News and Reports
-
ObsEva Receives FDA Clearance to Initiate Phase 2b Study of OBE2109 in Endometriosis
6 July 2016Download -
AnaptysBio Initiates Multiple Ascending Dose Cohorts in ANB020 Phase 1 Clinical Trial
6 July 2016Download -
Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
27 June 2016Download -
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections
16 June 2016Download -
Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs
22 March 2016Download -
Skyepharma to merge with Vectura Group
16 March 2016Download -
ARMO BioSciences Raises $50 Million Series C Financing
10 February 2016Download -
Kolltan Pharmaceuticals Provides Update on Clinical Pipeline, Corporate Developments and Near-Term Milestones
8 January 2016Download -
NUVASIVE to aquire Ellipse Technologies
6 January 2016Download -
Vascular Dynamics’ MobiusHD™ System Receives CE Mark for the Treatment of Resistant Hypertension
6 January 2016Download -
Allena Pharmaceuticals Raises $53 Million in Series C Financing
9 December 2015Download -
HBM co-leads CHF 60 million Series B financing of ObsEva
23 November 2015Download -
Curetis IPO priced at EUR 10.00 per Share; raises EUR 40 million
15 November 2015Download -
Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week
12 November 2015Download -
Advanced Accelerator Applications S.A. Announces Pricing of Initial
10 November 2015Download -
Ophthotech Completes Patient Recruitment of the Second Phase 3 Pivotal Trial of Fovista® Anti-PDGF Therapy in Combination with Lucentis® in Wet Age-Related Macular Degeneration
26 October 2015Download -
APR Applied Pharma Research (APR) announces the European Class III CE Mark approval of Nexodyn
16 October 2015Download -
Over 2000 Patients Treated with Ellipse Technologies? MAGEC® System
1 October 2015Download -
AAA Announces Positive Results From Phase 3 Study NETTER-1 Evaluating Lutathera in Patients with Advanced Midgut Neuroendocrine Tumors
27 September 2015Download -
AAA's Lutathera Phase III Meets Primary Endpoint and Data will be Presented in Presidential Session at ECC 2015
16 September 2015Download -
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
20 August 2015Download -
Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria
4 August 2015Download -
Gynesonics raises $43 million in equity financing
22 July 2015Download -
AnaptysBio secures $40 million series D financing
15 July 2015Download -
Celgene to acquire Receptos, advancing leadership in immune-inflammatory diseases
14 July 2015Download